A novel GHRH antagonist inhibited cell proliferation and key cancer signaling pathways (MAPK, Akt, GSK-3β) in prostate, breast, and lung cancer cell lines — comprehensive anticancer mechanism through GH-axis blockade.
Key findingA novel GHRH antagonist inhibited cell proliferation and key cancer signaling pathways (MAPK, Akt, GSK-3β) in prostate, breast, and lung cancer cell l
What the researchers found
A novel GHRH antagonist inhibited cell proliferation and key cancer signaling pathways (MAPK, Akt, GSK-3β) in prostate, breast, and lung cancer cell lines — comprehensive anticancer mechanism through GH-axis blockade.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
International journal of oncology, 39(4), 1025-32
Citation
Pozsgai, Eva; Schally, Andrew V; Hocsak, Eniko; Zarandi, Marta; Rick, Ferenc; Bellyei, Szabolcs. (2011). The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.. International journal of oncology, 39(4), 1025-32. https://doi.org/10.3892/ijo.2011.1098